Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73,819,979
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
10,506,228
-
Shares change
-
+1,150,045
-
Total reported value, excl. options
-
$469,323,200
-
Value change
-
+$57,833,259
-
Put/Call ratio
-
4.7%
-
Number of buys
-
59
-
Number of sells
-
-14
-
Price
-
$44.75
Significant Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q2 2020
89 filings reported holding RLMD - RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share as of Q2 2020.
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10,506,228 shares
of 73,819,979 outstanding shares and own 14% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (1,480,852 shares), Avoro Capital Advisors LLC (1,425,000 shares), BlackRock Inc. (1,216,765 shares), RA CAPITAL MANAGEMENT, L.P. (851,907 shares), VANGUARD GROUP INC (691,652 shares), VR Adviser, LLC (668,440 shares), TANG CAPITAL MANAGEMENT LLC (500,000 shares), PARSONS CAPITAL MANAGEMENT INC/RI (454,087 shares), Invesco Ltd. (322,741 shares), and BOXER CAPITAL, LLC (300,000 shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.